Pharmaceutical contamination in coastal and marine sediments is an increasing environmental issue. Thousands of biologically active substances continuously enter aquatic ecosystems through wastewater discharge, agricultural runoff, and improper disposal. Due to their persistence and continuous release, these contaminants accumulate in various matrices, including water and sediments, posing long-term ecological risks. Their presence can disrupt microbial communities, bioaccumulate in marine organisms, and heighten the risks of chronic exposure and antimicrobial resistance. To safeguard human, animal, and environmental health, it is crucial to develop accurate methodologies to understand pharmaceutical occurrence profiles and monitor their presence in coastal ecosystems. This study describes the development and validation of a sensitive UHPLC-TOF-MS method for screening and confirming pharmaceuticals in coastal sediments, following Commission Implementing Regulation (EU) 2021/808. Thirty analytes were targeted and evaluated for key performance parameters, including selectivity and sensitivity, linearity, repeatability, reproducibility, trueness, limit of detection (LOD), and limit of quantification (LOQ). Data analysis demonstrated high selectivity and sensitivity, with LODs ranging from 0.02 to 0.23 ng/g and LOQs from 0.06 to 0.69 ng/g. Recovery values at the LOD level ranged from 74.3 % for irbesartan to 115.4 % for indapamide, while repeatability and reproducibility were under 19.5 % and 29.2 %, respectively. All performance criteria met the requirements outlined in European guidelines. To evaluate the method's robustness, it was applied to 12 sediment samples collected from an estuary, with irbesartan detected in 5 samples.